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Abstract
Introduction: For efficient metastatic dissemination, tumor cells form invadopodia to degrade and move
through three-dimensional extracellular matrix. However, little is known about the conditions that favor invadopodia
formation. Here, we investigated the effect of β-adrenoceptor signaling - which allows cells to respond to stress
neurotransmitters - on the formation of invadopodia and examined the effect on tumor cell invasion.
Methods: To characterize the molecular and cellular mechanisms of β-adrenergic signaling on the invasive
properties of breast cancer cells, we used functional cellular assays to quantify invadopodia formation and
to evaluate cell invasion in two-dimensional and three-dimensional environments. The functional significance of
β-adrenergic regulation of invadopodia was investigated in an orthotopic mouse model of spontaneous breast
cancer metastasis.
Results: β-adrenoceptor activation increased the frequency of invadopodia-positive tumor cells and the number of
invadopodia per cell. The effects were selectively mediated by the β2-adrenoceptor subtype, which signaled through the
canonical Src pathway to regulate invadopodia formation. Increased invadopodia occurred at the expense of focal
adhesion formation, resulting in a switch to increased tumor cell invasion through three-dimensional extracellular matrix.
β2-adrenoceptor signaling increased invasion of tumor cells from explanted primary tumors through surrounding
extracellular matrix, suggesting a possible mechanism for the observed increased spontaneous tumor cell dissemination
in vivo. Selective antagonism of β2-adrenoceptors blocked invadopodia formation, suggesting a pharmacological
strategy to prevent tumor cell dissemination.
Conclusion: These findings provide insight into conditions that control tumor cell invasion by identifying signaling
through β2-adrenoceptors as a regulator of invadopodia formation. These findings suggest novel pharmacological
strategies for intervention, by using β-blockers to target β2-adrenoceptors to limit tumor cell dissemination and
metastasis.
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Introduction
Metastasis is the main cause of death from cancer, and
involves the dissemination of cancer cells from the
primary tumor to colonize distant tissues [1]. To aid
dissemination, cancer cells form specialized actin-rich
structures called invadopodia that facilitate invasion
through the basement membrane and surrounding
stroma [2]. Invadopodia produce and localize matrix
metalloproteases (MMPs) to focally degrade surrounding
extracellular matrix. Src has been shown to play a key
role in invadopodia formation and invasion [3, 4]. Src
may be recruited away from focal adhesions [5, 6],
resulting in a shift to invadopodia-mediated invasion,
which favors tumor cell movement through the sur-
rounding three-dimensional extracellular matrix and
leads to tumor cell dissemination to distant organs.
Tumor progression and metastasis are regulated by bi-
directional signaling between tumor cells and their sur-
rounding microenvironment [7]. β-adrenoceptors (βARs)
are found on both tumor cells and untransformed cells
in the tumor microenvironment, and allow for cellular
response to neural signals [8, 9]. Neurotransmitters includ-
ing noradrenaline and adrenaline are released during stress
and bind to βARs [10]. Activation of βAR induces intracel-
lular signaling cascades that accumulate cAMP, activate
PKA, and regulate gene transcription to modify cell behav-
ior [11]. βAR signaling drives metastasis [12–14], and Src
activation has been implicated in βAR regulation of metas-
tasis [15]. However, the cellular mechanisms by which
βARs drive tumor cell dissemination remain elusive.
To investigate, we explored the effect of βAR signaling
on the molecular and cellular mechanisms of tumor cell
invasion. Using functional assays we found that βAR sig-
naling enhanced invadopodia formation through canonical
Src signaling pathways. Increased invadopodia formation
was associated with loss of focal adhesions and enhanced
tumor cell invasion through three-dimensional extracellu-
lar matrix. These effects were selectively mediated by the
β2AR subtype, which enhanced tumor cell invasion from
primary mammary tumors and increased metastasis in
vivo. β2AR regulation of invadopodia could be reversed by
pharmacological blockade, suggesting a strategy to reduce
tumor cell dissemination in breast cancer.
Methods
Reagents
CGP-20712A dihydrochloride, ICI-118551 hydrochloride,
and xamoterol hemifumerate were sourced from Tocris
Bioscience (Bristol, UK); formoterol fumarate from BioNet
(Cornwall, UK); and PP2 Src inhibitor from Calbiochem
(Alexandria, Australia). Agonists were used at 0.5 μM and
antagonists at 0.05 μM unless otherwise stated. Other re-
agents and chemicals were from Sigma-Aldrich (Castle
Hill, Australia) unless otherwise stated.
Cell culture and transduction
The highly metastatic HM variant of MDA-MB-231
breast cancer cell line (described throughout as MDA-
MB-231) was a kind gift from Dr Zhou Ou, Fudan
University Shanghai Cancer Center, China [16, 17].
The cell line identity was verified by karyotyping
(CellBank Australia, Westmead, NSW Australia) and
transduced to express codon-optimized luciferase 2,
luc2 [13]. Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented
with 10 % fetal bovine serum (FBS). Cells were main-
tained at 37 °C, in a humidified environment with
5 % CO2. The 66cl4 mouse mammary adenocarcin-
oma cell line (a kind gift from Prof Robin Anderson,
Peter MacCallum Cancer Centre, East Melbourne, VIC,
Australia) was cultured in α-minimum essential
medium (Invitrogen, Scoresby, VIC) containing 10 %
FBS [12]. These cell lines are characteristic of triple-
negative breast cancer [18]. pLL5.0-LifeAct-GFP-2A-
luc2 was generated by ligation of a sequence encoding
the 2A cleavage peptide and luc2 immediately 3′ of
green fluorescent protein (GFP) in pLL5.0-LifeAct-
GFP [19]. The luc2 sequence was PCR amplified from
pGL4.10 (Promega, Madison, WI USA) using a modi-
fied 5′ primer that encoded the 2A peptide sequence
[20]. The product was sequence validated. Lentiviral
production was performed as described previously
[21] and a fluorescent population identified by
fluorescence-activated cell sorting.
Gene expression
RNA was extracted using the RNeasy kit (Qiagen Chadstone,
VIC Australia) and gene expression was quantified by
quantitative RT-PCR using the iScript One-Step RT-PCR
kit (Bio-Rad, Gladesville, NSW Australia) and Taqman
probes (ADRB1, Hs02330048_s1; Adrb1, Mm00431701_s1;
ADRB2, Hs00240532_s1; Adrb2, Mm02524224_s1; ADRB3,
Hs00609046_m1; Adrb3, Mm02601819_g1; Life Technolo-
gies, Tullamarine, VIC Australia) and run on a CFX96 Real
Time System (Bio-Rad). Triplicate determinations were
evaluated by threshold cycle analysis and expressed relative
to the housekeeping gene (ACTB, Hs99999903_m1; Actb,
Mm00607939).
cAMP assay
cAMP accumulation was quantified by the Alphascreen
cAMP kit (Perkin Elmer, Melbourne, VIC Australia)
as per the manufacturer’s instructions. Cells were
serum-starved overnight and treated with antagonists
in stimulation buffer for 30 minutes before addition
of agonists for 10 minutes at 37 °C. Cells were lysed
in ice-cold ethanol, which was evaporated before re-
constitution in detection buffer for cAMP assay.
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Fixed invadopodia assay
MDA-MB-231 cells expressing LifeAct-GFP-Luc2 were
serum-starved overnight. Cells were preincubated with
antagonists for 20 minutes before plating onto coverslips
coated with Alexa Fluor-tagged gelatin or fibronectin in
media containing 10 % serum, ± agonists or antagonists
for 5 hours. Cells were fixed in 4 % paraformaldehyde
and nuclei counterstained with 1 μg/ml Hoechst 33242.
Cells were imaged on an SP8 confocal microscope (Leica
Microsystems, North Ryde, NSW Australia) using a 63×
PL APO CS2 1.4NA objective with excitation at 405 nm,
488 nm, 561 nm, and 633 nm and emission detectors set
as follows: 415-485 PMT, 495-535 HyD, 570-635 PMT,
and 645-705 PMT. Images were captured using LAS AF
software version 3.2 (Leica Microsystems). Invadopodia
were defined as actin-positive puncta overlying de-
graded (fluorescence-negative) matrix. The frequency
of invadopodia-positive cells was manually counted in
eight random fields of view from three independent
experiments. N ≥80 cells per treatment were quanti-
fied for each experiment. To determine the number
of invadopodia per cell, image stacks were prepared
and submitted to the Invadopodia Analysis Server
[19], which uses a high-pass filter and threshold to
identify regions of high actin concentration that colo-
calize with matrix degradation to identify active inva-
dopodia. Average matrix fluorescence outside the cell
bodies was set to 500 arbitrary units to allow the
local difference values to be compared between extra-
cellular matrix preparations [19]. Images were not
preprocessed prior to submission to the Server. N
≥130 cells per treatment were quantified for each ex-
periment. Experiments were conducted in triplicate.
Immunofluorescence
Focal adhesions were localized in MDA-MB-231 cells
following fixation and permeabilization by incubating
with 10 μg/ml anti-paxillin antibody (clone 5H11;
Millipore, Bayswater, VIC Australia), followed by 1 μg/
ml Alexa Fluor 488-conjugated secondary antibody and
200 U/ml Alexa Fluor-647 phalloidin (Invitrogen) to co-
stain actin. Nuclei were counterstained with 1 μg/ml
Hoechst 33242. Cells were imaged using an SP8 confocal
microscope as already described. Focal adhesions were
measured in ImageJ software (National Institutes of
Health, Bethesda, MD USA) by drawing a region of
interest across the longest axis of each paxillin-positive
focal adhesion at the cell perimeter. Only adhesions
greater than 3 pixels long were counted. Focal adhesions
were analyzed from four random fields of view from
each of two independent experiments. No nonlinear ad-
justments were made during image processing and all
adjustments were applied to the entire image. Images
were cropped to a single cell for presentation in figures
without removing any additional image information.
β2AR was localized by immunostaining as described pre-
viously [12] in de-identified human breast cancer tissue
obtained under approval from the Institutional Review
Board. Samples were counterstained with anti-
macrophage antibody (0.7 μg/ml Ham56; Dako, North
Sydney, NSW Australia) to distinguish tumor cells from
stromal cells.
Two-dimensional migration assay
Serum-starved LifeAct-GFP+ MDA-MB-231 cells were
seeded on fibronectin-coated chamber slides and treated ±
agonists/antagonists. Cells were imaged on a Ti-Ex micro-
scope (Nikon Instruments, Melville, NY USA) using a 20×
Plan Apo 0.6NA objective with fluorescence filters GFP
excitation 470/40 and emission 525/50, red fluorescence
excitation 545/30 and emission 620/60, and far red excita-
tion 620/60 and emission 700/75. The microscope was fit-
ted with an incubation chamber heated to 37 °C and
humidified CO2 was supplied to the cells. Images were
captured every 20 minutes for 16 hours using a SPOT
Pursuit camera (Diagnostic Instruments, Victoria Park,
WA Australia) and MetaMorph 7.8.0 software (Molecular
Devices, Sunnyvale, CA USA). Time-series images were
reconstructed and cells tracked manually using ImageJ
software. No nonlinear adjustments were made during
image processing and all adjustments were applied to the
entire image. The experiment was conducted in duplicate.
Single-cell three-dimensional migration assay
Serum-starved LifeAct-GFP+ MDA-MB-231 cells were
resuspended in 1 mg/ml collagen (type I rat tail; Merk-
Millipore) ± agonists/antagonists and the matrix was set
at 37 °C for 20 minutes. Cells were imaged every 20 mi-
nutes for 16 hours using an A1R confocal microscope
(Nikon) using a 20× Plan Apo 0.6NA objective with a cor-
rection collar, with excitation 488 nm and an emission
505–545 BP filter. The microscope was fitted with an in-
cubation chamber heated to 37 °C and humidified CO2
was supplied to cells. Z-stacks of 100 μm in 20 μm steps
were captured using NIS Elements software (version 3.22;
Nikon Instruments). Three-dimensional images were re-
constructed in Imaris 7.6.4 software (Bitplane, Zurich
Switzerland) and cell migration was tracked. Protrusion-
positive cells were counted manually 6 hours after seeding.
Any cell with a protrusion longer than half the cell body
diameter was considered protrusion-positive. Images were
prepared as maximum intensity projections. No nonlinear
adjustments were made during image processing and all
adjustments were applied to the entire image. Images were
cropped to a single cell for presentation in figures without
removing any additional image information. N ≥20 cells
were quantified per treatment. Experiments were con-
ducted in triplicate.
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Metastasis models and explants
All procedures involving mice were carried out under
protocols approved by the Institutional Animal Ethics
Committee and in accordance with National Health and
Medical Research Council animal ethics guidelines.
MDA-MB-231 breast cancer cells were injected into the
left fourth mammary fat pad of BALB/c nude mice as
described previously [12]. Formoterol (5 mg/kg/day) or
saline placebo was injected once daily by subcutaneous
injection. Bioluminescence imaging was used to track
tumor growth and metastatic progression using an IVIS
Lumina II (Perkin Elmer) as described previously [12,
17]. Metastasis was confirmed by ex vivo imaging and
hematoxylin and eosin staining. For analysis of tumor
cell invasion from explanted primary tumors, a subset of
mice were anesthetized on day 9 of mammary tumor
growth and euthanized. Tumors were surgically removed
from the mammary fat pad and embedded in 1 mg/ml
collagen ± 0.5 μM formoterol. Explants were maintained
at 37 °C with 5 % CO2 and imaged every 2 days over a
period of 8 days using an A1R confocal microscope
(Nikon) as already described. Z-stacks were cap-
tured over 250 μm at 50 μm steps with large image for-
mat stitching of a 7 × 7 field of view grid. Time series
images were reconstructed and analyzed using the Fiji
distribution of ImageJ with StackReg plugin. Tumor
boundaries were defined on the image that was acquired
on day 0 and the area of tumor cell invasion of sur-
rounding extracellular matrix outside this region of
interest was then determined at subsequent time points.
Five tumors were quantified per treatment. Two experi-
mental replicates were conducted.
Statistical analyses
Generalized linear models were used to assess the rela-
tionship between treatments and experimental response
[22]. The number of invadopodia per cell and the fre-
quency of invadopodia-positive cells were modeled by
binomial (logit link) and Poisson (log link) generalized
linear models, respectively. Treatment differences for
single continuous responses such as cell displacement
and cAMP accumulation were analyzed by analysis of
variance. For statistical analysis of in vivo metastatic pro-
gression and ex vivo invasion, the impact of β2AR stimu-
lation over time was analyzed using the linear model:
ln Yð Þ ¼ β0 þ β1t þ β2I formoterolf gx t þ ε
where Y is the luciferase activity (total flux, Fig. 5b) or
the area of tumor cell invasion outside the tumor
boundaries (Fig. 5c), β0 is the intercept parameter, t is
time, I{formoterol} (taking values 0 or 1) indicates the
presence of formoterol, and ε is a Gaussian random
error. For the fitted models, we report estimated
regression coefficients quantifying the relationship be-
tween the response and treatments, and the corresponding
p values for testing the null hypothesis of no treatment ef-
fect. For experiments involving multiple treatments,
we tested simultaneous differences between pairs of
treatment effects (Tukey’s all-pair comparisons) [23].
Confidence intervals and p values were adjusted at the
nominal 5 % significance level for multiple testing.
Statistical analysis was carried out in the R computing
environment [24]. Generalized linear models were fit-
ted using the routine glm while multiple comparisons
used the routine glht in the package multicomp [25].
Results and Discussion
We first confirmed expression of βAR in MDA-MB-231
and 66cl4 tumor cells, which are breast cancer cells lines
that respond to stress signaling with increased
metastasis from primary orthotopic mammary tumors
[12, 13]. Expression analyses found higher β2AR than
β1AR transcription in MDA-MB-231 cells, while 66cl4
expressed only β2AR (Fig. 1a). β3AR was not detectable
in either cell line, although priming from these probes
has been confirmed [26, 27]. Immunostaining confirmed
that tumor cells from an archival clinical sample
expressed β2AR, suggesting that findings may be rele-
vant to human breast cancer (Fig. 1b). To evaluate re-
ceptor functionality, we treated tumor cells with βAR
ligands and quantified the effect on intracellular cAMP
accumulation. In each cell line, treatment with the non-
selective βAR agonist isoproterenol increased cAMP ac-
cumulation (Fig. 1c, d), consistent with previous studies
[28]. This effect was blocked by the nonselective βAR
antagonist propranolol or the β2AR-selective antagonist
ICI-188551. Treatment with β1AR-selective antagonist
CGP-20712A or β3AR-selective antagonist L748337 did
not block cAMP accumulation (Fig. 1c, d). These find-
ings confirm that β2AR is the dominant functional βAR
in these breast cancer cell lines.
To investigate the role of βAR signaling in invadopo-
dia formation, LifeAct-GFP+ MDA-MB-231 cells were
plated on a fluorescent gelatin matrix and the effect of
β-agonist isoproterenol on matrix degradation was eval-
uated (Fig. 2a). While actin-rich puncta were identified
in the entire population, only 16 % (± 4 %) of tumor
cells produced active invadopodia as defined by degrad-
ation of underlying matrix fluorescence (Fig. 2a, b).
Treatment with isoproterenol led to an increase in the
frequency of invadopodia-positive cells, with a maximum
increase of 2.5-fold in response to 0.5 μM isoproterenol
(Fig. 2b). In addition to increasing the frequency of
invadopodia-positive cells in the population (Fig. 2b, c),
isoproterenol also increased the average number of inva-
dopodia per cell by 2.7-fold (Fig. 2d). Treatment with
the nonselective β-blocker propranolol blocked the effect
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of isoproterenol on both the frequency of invadopodia-
positive cells and the number of invadopodia per cell
(Fig. 2c, d). This confirms that isoproterenol signals via
βAR to increase invadopodia formation. To confirm the
βAR subtype that mediates this effect, MDA-MB-231
cells were treated with selective antagonists and the ef-
fect on invadopodia was evaluated. β2AR-selective antag-
onist ICI-118551 blocked the increase in invadopodia
formation in response to isoproterenol, whereas there
was no effect of β1AR-selective antagonist CGP-20712A
(Fig. 2e). To determine whether β2AR signaling is suffi-
cient to induce invadopodia formation, cells were treated
with selective βAR agonists. β2AR-selective agonist for-
moterol – but not β1AR-selective agonist xamoterol –
induced invadopodia formation (Fig. 2f, g), confirming a
key role for β2AR signaling in the formation of invado-
podia in these cells.
Formation of invadopodia requires adhesion proteins
that may be sequestered from focal adhesions [6]. To in-
vestigate the effect of βAR signaling on focal adhesions
we treated breast cancer cells with isoproterenol and
used immunostaining to quantify the number and
length of paxillin-positive focal adhesions (Fig. 3a).
Isoproterenol resulted in a concentration-dependent
decrease in adhesion length and decreased number of
focal adhesions per cell (Fig. 3a, b). Loss of focal ad-
hesion-associated proteins has been linked to a de-
creased frequency of focal adhesions and reduced
capacity for cell migration on two-dimensional surfaces
[29]. Consistent with the change in focal adhesions hav-
ing a functional effect on cell movement, isoproterenol
decreased the migration of cancer cells on a two-
dimensional fibronectin surface (Fig. 3c, d).
These findings suggest that β2AR signaling induces an
invasive phenotype that favors tumor cell invasion in
three-dimensional environments. To investigate this,
MDA-MB-231 breast cancer cells were embedded in
collagen matrix and cell locomotion was tracked over
time. Under control conditions, cells remained rounded
with little displacement from the position of origin
(Fig. 4a, b). Treatment with β2AR-selective agonist for-
moterol induced cancer cells to elongate and form
b
66cl4
a
MDA-MB-231c d
2AR Macrophage Merge
Fig. 1 Breast cancer cells have functional β2-adrenoceptors (β2AR). a ADRB1, ADRB2, and ADRB3 mRNA transcript levels were quantified by
quantitative RT-PCR, with expression normalized to ACTB. b Immunostaining of β2AR and macrophages in archival breast cancer tissue. Scale
bar: 100 μm. c, d cAMP accumulation was quantified in c 66cl4 cells and d MDA-MB-231 cells after treatment with vehicle, or 10 nM
isoproterenol ± 1 μM antagonists including propranolol (nonselective), CGP-20712A (β1AR selective), ICI-118551 (β2AR selective), or L748337
(β3AR selective). N = 3. Error bars: standard error of the mean (SEM). ND: not detected. *p <0.05 and **p <0.01
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protrusions (Fig. 4a) and increased cell displacement
over time (Fig. 4b, c), indicating that β2AR signaling is
sufficient to induce invasion of MDA-MB-231 breast
cancer cells. Treatment with isoproterenol similarly in-
duced cellular protrusion formation and these effects
were blocked by the β2AR-selective antagonist ICI-
b
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Fig. 2 β2AR signaling induces invadopodia formation. a LifeAct-GFP+ MDA-MB-231 cells were plated on Alexa-568-labelled gelatin and active
invadopodia were identified by confocal microscopy as LifeAct-GFP+ puncta colocalized with degraded gelatin (loss of red fluorescence;
see inset). Representative images are shown. Scale bar: 20 μm, or 5 μm for inset panel. b The frequency of invadopodia-positive cells was
determined in cells treated with isoproterenol (Iso). c, d Cells were treated with 0.5 μM Iso ± 0.05 μM propranolol (Prop), and c the frequency of
invadopodia-positive cells was determined or d the number of invadopodia per cell was determined (N >130 cells per treatment). e Cells were
treated with Iso ± β1AR-selective antagonist CGP-20712A (CGP) or β2AR-selective antagonist ICI-118551 (ICI) and the effect on invadopodia formation
was quantified. f, g Cells were treated with Iso, β1AR-selective agonist xamoterol, or β2AR-selective agonist formoterol and f the effect on invadopodia
was quantified. g Representative confocal sections are shown. Inset shows GFP+ active invadopodia on degraded matrix (loss of red fluorescence).
Scale bar: 20 μm, or 5 μm for inset panels. N > 80 cells per treatment unless otherwise stated. Experiments were conducted in triplicate. Error bars:
SEM. *p <0.05, **p <0.01 and ***p <0.001
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118551, confirming a role for β2AR signaling in these ef-
fects on cell invasion through a three-dimensional colla-
gen matrix. By identifying differential effects of βAR
signaling between cell movement on two-dimensional sur-
faces compared with migration in three-dimensional
environments, these findings may reconcile seemingly in-
consistent observations for the effects of endogenous
neurotransmitters and βAR-selective agonists on tumor
cell migration [30–33]. Because movement in three-
dimensional environments reflects processes that are
a b
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Fig. 3 β2AR signaling decreases focal adhesions and decreases migration on two-dimensional surfaces. a Representative confocal sections of
tumor cells stained for actin and paxillin to identify focal adhesions. Scale bar: 10 μm. Square brackets in inset identify focal adhesions. b The
effect of isoproterenol on focal adhesion length and number of adhesions per cell was quantified. c The effect of isoproterenol on cell migration on
two-dimensional fibronectin surfaces over time was quantified. d Representative time series images of cells treated with vehicle or isoproterenol. Red
cross marks the location of the cell at the commencement of treatment. Time in hours is indicated. N > 20 cells per condition. Error bars: SEM. *p <0.05,
**p <0.01 and ***p <0.001
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required for tumor cell intravasation and extravasation
during metastasis, these findings suggest a cellular mech-
anism for observations that βAR signaling drives breast
cancer progression [12, 13].
Src activity plays a key role in invadopodia formation
[4, 6], and has been implicated in βAR regulation of
ovarian cancer invasion, although the cellular mechanisms
are unclear [15]. To investigate the role of Src in β2AR
Fig. 4 β2AR-induced invadopodia formation is dependent on Src and increases tumor cell invasion in a three-dimensional collagen matrix.
a Representative time series images acquired by confocal microscopy showing the effect of formotorol or isoproterenol (Iso) ± 0.05 μM
ICI-118551 (ICI) on development of cell protrusions. Time in hours is indicated. b Graphical representation of track measurements is shown
for 20 cells in each condition. c Quantification of cell displacement from the point of origin. d, e Representative maximum intensity projections
of LifeAct-GFP+ MDA-MB-231 cells treated with 0.5 μM PP2 ± 0.5 μM formoterol and examined for active invadopodia. Inset shows GFP+ green
puncta (active invadopodia that have degraded underlying matrix) or yellow puncta (inactive invadopodia where GFP+ puncta have not degraded the
underlying red fluorescent matrix). Scale bar: 10 μm, or 5 μm for inset panels. e The percentage of invadopodia positive cells was quantified. N >80
cells per condition. f Graphical representation of track measurements after cells were embedded in 1 mg/ml collagen matrix and treated with 0.5μΜ
formoterol ± PP2 Src inhibitor. N = 20 cells per condition. Error bars: SEM. *p <0.05 and **p <0.01
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regulation of invadopodia, MDA-MB-231 cells were pre-
treated with the Src inhibitor PP2 prior to treatment with
formoterol. PP2 treatment blocked the effect of β2AR
stimulation on the frequency of invadopodia (Fig. 4d, e),
as seen by loss of matrix fluorescence. Treatment with
PP2 alone did not significantly change the frequency of
invadopodia compared to treatment with vehicle. Treat-
ment with PP2 also blocked the effect of formoterol on in-
vasion of cells in three-dimensional collagen matrix
(Fig. 4f), demonstrating that Src is essential for β2AR-me-
diated invasion. These findings indicate that β2AR signal-
ing regulates invadopodia formation and tumor cell
invasion through canonical Src signaling pathways. βAR ac-
tivation was recently shown to phosphorylate Src at Y416 in
addition to S17 [15], suggesting that characterization of the
activation status of Src will contribute to a more complete
understanding of the molecular mechanisms involved.
Additional insight may be gained from clarifying other
β2AR-induced molecular changes that may amplify effects
on tumor cell dissemination. For example, norepinephrine
was shown to protect cancer cells from anoikis by
activating and relocalizing focal adhesion kinase [34]. Coor-
dinated regulation of invadopodia formation and reduced
anoikis in response to β2AR-mediated neural signaling may
serve to amplify the effects on tumor cell dissemination
and cancer progression.
To investigate the impact of β2AR regulation of tumor
cell invasion in vivo, bioluminescence imaging was used
to track the effect of β2AR-selective agonist formoterol
on metastatic progression in an orthotopic xenograft
model of breast cancer. Mice were implanted with
luciferase-tagged MDA-MB-231 cells into the left fourth
mammary fat pad and spontaneous metastasis was
tracked by bioluminescence imaging using 1-second
exposure to detect signals from primary tumors and 60-
second exposure to detect signals from metastases
(Fig. 5a). Treatment with formoterol during tumor de-
velopment accelerated the formation of metastasis
(Fig. 5b). To examine whether increased metastasis was
linked to increased tumor cell invasion, a subset of
mammary tumors were surgically resected 9 days after
tumor cell inoculation, before the onset of metastasis,
Fig. 5 β2AR signaling induces tumor cell invasion and metastasis from primary mammary tumors. a Representative image of the orthotopic
metastasis model. Luciferase-tagged tumor cells were injected into the fourth mammary fat pad (PT) and spontaneous metastases to the lymph
node and lung (Met) were detected by optical bioluminescence imaging. Lower body exposure: 1 second. Upper body exposure: 60 seconds.
Black bar separates images taken with two different exposures. b Mice were treated daily with 5 mg/kg formoterol (or saline vehicle) during
tumor development and the effect of distant metastasis was quantified over time by bioluminescence imaging and expressed relative to primary
tumor size. N = 5 at each time-point. c Primary tumors were resected from the mammary fat pad of vehicle vs. formoterol-treated mice at day 10
after tumor cell injection and embedded in a three-dimensional collagen matrix. Invasion of LifeAct-GFP+ tumor cells beyond explant boundaries
into the surrounding collagen (arrows) was imaged over 8 days by confocal microscopy and quantified. N = 5 at each time point. Error bars: SEM.
***p <0.001
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and embedded in a three-dimensional collagen matrix.
In contrast to tumors from vehicle-treated mice, which
demonstrated minimal invasion of cells into the sur-
rounding extracellular matrix over the 8-day imaging
period, tumors from mice treated with formoterol had
rapid invasion of tumor cells into the surrounding
matrix (Fig. 5c). This shows that β2AR signaling in-
creases dissemination from explanted tumors, suggesting
a possible mechanism for increased distant metastasis.
While recent studies of βAR-mediated stress biology
on cancer progression have focused on the impact of
neural signaling on stromal cells in the tumor micro-
environment [12, 14, 35, 36], the findings presented here
demonstrate that tumor cells are directly responsive to
βAR signaling. By driving a shift away from focal adhe-
sions to invadopodia formation, β2AR signaling would
favor tumor cells with enhanced capacity for invasion
through the three-dimensional extracellular matrix of
the tumor microenvironment. Metastasis is a highly inef-
ficient process and requires successful completion of a
series of inter-connected steps including dissemination
from the primary tumor, survival in circulation, extrava-
sation, and colonization at distant sites [37–39]. Failure
at any stage of metastasis will result in failure of the
entire process [40]. By increasing both the density of
invadopodia per cell and the frequency of invadopodia-
positive cells in the tumor cell population, β2AR signal-
ing may promote metastasis by enhancing the invasive
capacity of cells in the tumor.
These findings suggest that blocking tumor cell re-
sponsiveness to stress signaling may protect against
tumor cell invasion and metastasis. Specifically, the
effects of β2AR signaling on invadopodia formation
were reversed by β-blockade, providing a cellular
mechanism for clinical observations that pharmaco-
logical β-blockade was linked to improved cancer out-
comes [41–43]. Retrospective epidemiological studies
found that β-blocker treatment of comorbid hypertension
was associated with reduced metastasis and improved
survival in different cancer types including breast and
prostate cancers and melanoma (reviewed in [44]). The
current findings show that β-blockers act directly on can-
cer cells to decrease their invasiveness. While not exclud-
ing that β-blockade regulates cancer progression through
effects on the tumor microenvironment (e.g., modulating
recruitment of inflammatory cells or angiogenesis)
[12, 35], these findings suggest that β-blockers may
be optimally targeted to patients with high tumor cell
expression of β2AR. Recent clinical practice has pre-
ferred the use of β1-selective blockers for treatment
of hypertension, to avoid adverse effects on broncho-
constriction [45]. The findings presented here suggest
that use of nonselective β-blockers such as propran-
olol may be required to favorably impact cancer
outcomes. Additionally these findings may warrant
the development of novel β2-selective blockers that
may be targeted to tumor cells to avoid adverse side
effects. Finally, these findings suggest that it may be
important to consider the effect of clinically used
β2AR agonists (e.g., by asthmatics for bronchodilation)
on cancer progression.
Conclusions
Here, we present evidence that β2AR signaling drives a
switch from focal adhesions to invadopodia formation in
breast cancer cells to increase cell invasion in three-
dimensional environments. These findings suggest that
β2AR may be a key receptor for transmission of neural
signals from the tumor microenvironment to regulate
behavior of tumor cells. The findings provide a plausible
mechanism for accumulating evidence that chronic
stress promotes cancer progression and metastasis
[12, 35, 46, 47], and suggest that selective pharmaco-
logical blockade of β2AR signaling pathways may be
important to slow cancer progression.
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